Perhexiline Therapy in Patients with Type 2 Diabetes: Incremental Insulin Resistance despite Potentiation of Nitric Oxide Signaling.

Chong, Cher-Rin; Liu, Saifei; Imam, Hasan; Heresztyn, Tamila; Sallustio, Benedetta C; Chirkov, Yuliy Y; Horowitz, John D

Chong, Cher-Rin; Liu, Saifei; Imam, Hasan; Heresztyn, Tamila; Sallustio, Benedetta C; Chirkov, Yuliy Y; Horowitz, John D.

Afiliación

Chong CR; Adelaide Medical School, The University of Adelaide, Adelaide 5000, Australia.
Liu S; Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South 5011, Australia.
Imam H; Adelaide Medical School, The University of Adelaide, Adelaide 5000, Australia.
Heresztyn T; Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South 5011, Australia.
Sallustio BC; Adelaide Medical School, The University of Adelaide, Adelaide 5000, Australia.
Chirkov YY; Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South 5011, Australia.
Horowitz JD; Adelaide Medical School, The University of Adelaide, Adelaide 5000, Australia.

Biomedicines ; 10(10)2022 Sep 23.

Article en En | MEDLINE | ID: mdl-36289640

Palabras clave

insulin resistance; nitric oxide; perhexiline; type 2 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google